Search results
Results from the WOW.Com Content Network
Castration-resistant prostate cancer (CRPC) is prostate cancer that progresses despite extremely low testosterone in the body often due to medical castration. [4] Unlike many other types of prostate cancer, CRPC do not need normal testosterone levels, but they still require regular androgen receptors (AR).
This combination likely improves overall and cancer-specific survival by slowing the spread of the cancer. However, taxane-based chemotherapy may cause an increase in side effects. [45] Medications that block the production of adrenal androgens such as DHEA include ketoconazole and aminoglutethimide. Because the adrenal glands make only about 5 ...
Prostate cancer is the most diagnosed cancer in men in over half of the world's countries, and the leading cause of cancer death in men in around a quarter of countries. [ 91 ] Prostate cancer is rare in those under 40 years old, [ 92 ] and most cases occur in those over 60 years, [ 2 ] with the average person diagnosed at 67. [ 93 ]
Cancer Stem Cell phenotypes are associated with disease recurrence, metastasis, and cell survival in circulation as Circulating tumor cells. Thus, activation of these programs via inhibition of the androgen axis provides a mechanism by which tumor cells can adapt to promote disease recurrence and progression.
Prostate cancer (PC) is the most common form of non-cutaneous malignant cancer in males, and is the second leading cause of cancer deaths in males. [12] PC3 cells have been utilized to research aggressive and castration-resistant forms of pancreatic cancer.
PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]
Castration in the genital modification and mutilation context is the removal of the testicles. Occasionally the term is also used to refer to penis removal, but that is less common. Castration has been performed in many cultures throughout history, but is now rare. It should not be confused with chemical castration.